Payment overview · 2025
General Payments
$316.19
11 reported records · 7 companies
Healthcare provider profile · identity verified
Chi-Whei Lin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAGUNA HILLS, CA · NPI 1114057254
Verified facts
What the public records show
CMS Open Payments records show Chi-Whei Lin, M.D. received $316.19 in general payments during 2025 across 11 reported records.
REVANCE THERAPEUTICS, INC. accounted for 51.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Paxlovid, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $162.69 | 51.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.37 | 14.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.63 | 9.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.14 | 6.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.86 | 6.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.70 | 5.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.80 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $316.19 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $162.69 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.37 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.63 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 52 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
52 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 429 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 404 | 121 |
| Losartan Potassium | Losartan Potassium | 363 | 105 |
| Meloxicam | Meloxicam | 289 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 72 |
| Omeprazole | Omeprazole | 237 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 222 | 55 |
| Metformin Hcl | Metformin Hcl | 174 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 40 |
| Lisinopril | Lisinopril | 110 | 26 |
| Simvastatin | Simvastatin | 100 | 24 |
| Finasteride | Finasteride | 99 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 27 |
| Azithromycin | Azithromycin | 88 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 35 |
| Furosemide | Furosemide | 80 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 16 |
| Alprazolam | Alprazolam | 72 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 23 |
| Januvia | Sitagliptin Phosphate | 68 | 17 |
| Montelukast Sodium | Montelukast Sodium | 64 | 21 |
| Atenolol | Atenolol | 57 | 17 |
| Lovastatin | Lovastatin | 57 | 17 |
| Gabapentin | Gabapentin | 56 | 18 |
| Ozempic | Semaglutide | 53 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 52 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 12 |
| Eliquis | Apixaban | 50 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 15 |
| Potassium Chloride | Potassium Chloride | 48 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 34 |
| Ezetimibe | Ezetimibe | 47 | 15 |
| Allopurinol | Allopurinol | 46 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 25 |
| Alendronate Sodium | Alendronate Sodium | 44 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 11 |
| Donepezil Hcl | Donepezil Hcl | 40 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 15 |
| Glipizide Er | Glipizide | 38 | 12 |
| Famotidine | Famotidine | 37 | 12 |
| Methylprednisolone | Methylprednisolone | 36 | 27 |
| Mirtazapine | Mirtazapine | 36 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | 12 |
| Trazodone Hcl | Trazodone Hcl | 33 | 12 |
| Temazepam | Temazepam | 32 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | 11 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 11 |
| Glipizide | Glipizide | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Hydrocortisone | Hydrocortisone | 21 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | 12 |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Prolia | Denosumab | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $316.19 · 11 records | REVANCE THERAPEUTICS, INC. | Cologuard Collection Kit, DAXXIFY, JARDIANCE, KISUNLA, PAXLOVID, TRELEGY ELLIPTA, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error